Some source checks need review. The dated references remain below. Confirm current guidance with the original source and your care team. Current policy statements are withheld where their checks have expired.
BPC-157: what does the human result establish?
This source check needs review. Confirm current guidance, sport rules and the exact product route with the original source before relying on a dated summary. This dated summary provides background on the comparison.
Dated source summary
The human knee-pain report we reviewed was retrospective and involved injections into a joint, with some participants receiving a combination. It does not establish the effects of another route, a current retail or compounded product, or repair of a tendon or ligament.
Keep subjective symptom change, structural healing and safety separate. FDA's scientific briefing also has its own nominated-use and route scope; it is not a treatment guideline for your injury. This is a bounded appraisal of the cited sources, not a claim that no other human report exists.
TB-500: identity comes before the headline
This source check needs review. Confirm current guidance, sport rules and the exact product route with the original source before relying on a dated summary. This dated summary provides background on the comparison.
Dated source summary
Identify the exact peptide material, sequence, formulation and route behind the label. Do not treat a result for full-length thymosin beta-4 as proof for a different fragment or a product marketed as TB-500.
The current policy appendix defines the material and routes within its limited scope. That identity work does not itself establish a human recovery benefit or qualify a particular pharmacy offer.
Wolverine vs GLOW vs KLOW peptide stacks
The names “Wolverine peptide,” “Wolverine blend” and “Wolverine stack” show up in recovery discussions. McGill uses Wolverine stack for BPC-157 paired with TB-500. Human evidence for either ingredient leaves the effects of the combination uncertain.
For GLOW vs KLOW, start with what each specific label claims. In a December 2025 notice, Health Canada listed PHX Labs GLOW as BPC-157, TB-500 and GHK-Cu. It listed PHX Labs KLOW with those three ingredients plus KPV. “GLOW peptide,” “GLOW blend,” “GLOW stack,” “KLOW peptide,” “KLOW blend” and “KLOW stack” are informal names. These ingredient lists describe the labels in that notice.
In November 2026, Australia’s Therapeutic Goods Administration detected no TB-500 in the tested Synedica samples labelled KLOW and Barbie KLOW, although those products listed it. The finding applies to the samples the regulator tested. The label, lab findings and evidence from human studies answer different questions.
Hormone changes and peptide stacks
This source check needs review. Confirm current guidance, sport rules and the exact product route with the original source before relying on a dated summary. This dated summary provides background on the comparison.
Dated source summary
An FDA-approved medicine has a product-specific indication and labeling. The somatropin and tesamorelin labels cited here do not turn those products into general injury-recovery or muscle-enhancement recommendations.
A hormone or biomarker result also does not demonstrate better healing, function or long-term suitability. Combining two ingredients does not combine their evidence into proof for the mixture. Ask for the exact intervention and outcome before judging a stack.
Oral collagen: preparation and outcome matter
The cited Achilles pilot studied a particular preparation alongside an exercise program. The healthy-training study measured tendon size, muscle thickness, strength and stiffness, with different findings across those outcomes.
Neither is a reason to score every collagen brand as if it had demonstrated injury repair. Label and purchase facts can be described without that claim. Keep the nutrition question, the finished-product identity and any proposed treatment claim separate.
A broad repair claim is not an indication
Gut symptoms, dental problems, serious burns and specialist chronic wounds are not the same consumer decision as exercise soreness or injury rehabilitation. A study in one condition cannot be transferred to another simply because both use the word healing.
Use the relevant treating service for those concerns. This Recovery comparison does not turn every advertised repair use into a product category or a purchase recommendation.
PRP, cells and exosomes are different interventions
A procedure, a cell-based or exosome product and a peptide formulation are not interchangeable offers. Ask for the exact intervention, proposed indication, current status and evidence for the outcome being promised.
FDA's regenerative-medicine consumer information raises specific product and oversight questions. It is not a basis to rank clinics here or to assume that another type of procedure is an equivalent recovery alternative.
Competitive-sport rules are a separate check
Use your sport's governing rules and the list that applies on the date you compete. WADA's 2026 list includes non-approved substances and several peptide/hormone categories; a prescription or a policy about compounding does not automatically settle a sport-rules question.
USADA also explains supplement risks and the limits of certification. Verify the exact product and program scope, and ask about any required therapeutic-use process before use. We do not guarantee that a product is permitted or risk-free.
Current policy, product compliance and benefit are separate
This source check needs review. Confirm current guidance, sport rules and the exact product route with the original source before relying on a dated summary. This dated summary provides background on the comparison.
Dated policy summary
On October 30, 2026, HHS announced a draft/interim enforcement-discretion policy for specified peptide bulk substances under defined conditions. The policy and appendices address exact identities, routes and 503A compounding circumstances. The notice describes it as nonbinding.
This is not FDA marketing approval or proof of recovery benefit. It also does not establish that a particular offered product meets every condition. Recheck the current policy, the exact treating/dispensing route and the intended use; old blanket statements and new marketing headlines can both miss important scope.
BPC-157 advertising audit: what three public pages disclose
Some dated source checks need review. Current claims are withheld where their bindings are unavailable. This is a small convenience sample of seller advertising, not a market survey, product review, provider qualification or recommendation. Any listed amounts are seller claims, not verified patient bills or complete treatment costs. We do not rank these offers.
Read the clinical and policy limits first
BPC-157 products are not FDA-approved. In its July 2026 scientific briefing, FDA found insufficient clinical safety information for the BPC-157 substances and routes it reviewed, and described possible product quality and immune-response concerns. That review does not establish the safety or injury benefit of any of the advertised vials. FDA scientific briefing.
HHS's interim policy identifies BPC-157 acetate for certain patient-specific compounding circumstances under stated conditions. It is not FDA product approval and does not establish that any seller here meets those conditions. HHS interim policy.
For an injury, start with care and rehabilitation. For tendon symptoms, read the tendon and ligament guide.
Promise
The dated source check for this seller is missing, changed or expired. Current presentation and price are unknown here.
Not independently established for this seller:
- Named dispensing pharmacy and named prescriber
- Actual active material, acetate or other salt, and complete finished formula
- Lot-specific certificate of analysis and product quality
- Applicable licenses and whether this exact arrangement meets policy conditions
- Patient eligibility, location availability, taxes, consultations or labs, other required charges, cancellation or refund terms, and continuing shipment obligations
Source: Promise public page (seller marketing). Citation only; the link does not endorse or qualify the seller.
System Labs
The dated source check for this seller is missing, changed or expired. Current presentation and price are unknown here.
Not independently established for this seller:
- Named dispensing pharmacy and named prescriber
- Actual active material, acetate or other salt, and complete finished formula
- Lot-specific certificate of analysis and product quality
- Applicable licenses and whether this exact arrangement meets policy conditions
- Patient eligibility, location availability, taxes, consultations or labs, other required charges, cancellation or refund terms, and continuing shipment obligations
Source: System Labs public page (seller marketing). Citation only; the link does not endorse or qualify the seller.
MyFit-Rx
The dated source check for this seller is missing, changed or expired. Current presentation and price are unknown here.
Not independently established for this seller:
- Named dispensing pharmacy and named prescriber
- Actual active material, acetate or other salt, and complete finished formula
- Lot-specific certificate of analysis and product quality
- Applicable licenses and whether this exact arrangement meets policy conditions
- Patient eligibility, location availability, taxes, consultations or labs, other required charges, cancellation or refund terms, and continuing shipment obligations
Source: MyFit-Rx public page (seller marketing). Citation only; the link does not endorse or qualify the seller.
First shipment, 28-day renewal and monthly terms cannot be turned into one fair total from these pages. Ask a licensed clinician about care choices, and use the product and access checks before relying on any advertised arrangement.
Match the evidence to the person and purpose
A healthy-adult training study, a retrospective pain report and a narrow prescription indication do not answer every pregnancy, adolescent, older-adult, postoperative or chronic-condition question. Discuss those circumstances before treating a general claim as personal guidance.
For a tested athlete, sport rules add another decision. No ingredient name, source country or certificate by itself establishes suitability, effectiveness or lawful access for a particular offer.
Use a claim-matching checklist
Name the proposed benefit and check the people studied, exact material and route, comparison, measured outcome, duration and uncertainty. Then ask whether the product offered today is actually the one the evidence describes.
Unknowns stay unknown. We have not published Recovery stars or qualified an exact product recommendation, and this guide does not promise personal treatment results.
Where to go next
Sources and dates
The source date describes the original material; the review date records our check. A dated source summary is not continuous monitoring, product testing or confirmation of current purchase terms.
- [1]Lee and colleagues: retrospective BPC-157 knee-pain report · Source date: 2021 · Reviewed
Retrospective intra-articular knee-pain observations, not proof of tendon repair or another finished product/route.
- [2]FDA: July 2026 BPC-157 scientific briefing · Source date: July 23-24, 2026 meeting · Reviewed
Nominated uses and route-specific scientific appraisal; not a Recovery clinical guideline.
- [3]FDA: compounding substances and safety concerns · Source date: Source date is shown on the original page · Reviewed
Substance/route-specific safety gaps; read alongside later policy. No blanket inference of current legal status.
- [4]HHS: interim peptide compounding policy and appendices · Source date: October 2026 policy document · Reviewed
Conditional enforcement-discretion context for specified 503A products, identities and routes; not marketing approval or recovery efficacy.
- [5]Federal Register: HHS peptide-policy notice · Source date: October 30, 2026 · Reviewed
Notice calls the policy draft/interim and nonbinding; current policy must be checked separately from a specific offer.
- [6]Health Canada: unauthorized peptide products seized at Rize Fitness · Source date: 2025-12-24 · Reviewed
Specific PHX Labs GLOW and KLOW label descriptions in a Health Canada seizure notice. The reported label contents do not establish the ingredients of any other product.
- [7]McGill University Office for Science and Society: Wolverine peptide nickname · Source date: Source date shown on original page · Reviewed
Nickname usage only: the source describes Wolverine stack as a pairing of BPC-157 and TB-500. It is not evidence that the combination improves human recovery.
- [8]Therapeutic Goods Administration: testing of unapproved peptide products · Source date: 2026-11-05 · Reviewed
TGA reports laboratory findings for tested Synedica samples labelled KLOW and Barbie KLOW. The findings apply to the tested products and do not establish a brand-wide or name-wide formulation.
- [9]FDA: Genotropin prescribing information · Source date: Revised July 2025 · Reviewed
Indication-bound somatropin labeling, not ordinary recovery or enhancement.
- [10]FDA: Egrifta WR prescribing information · Source date: 2025 label · Reviewed
Tesamorelin product/indication scope, not general recovery; formulations are distinct.
- [11]Jerger and colleagues: collagen plus resistance training · Source date: 2022 · Reviewed
Healthy male training study: tendon size and muscle thickness differed; strength and stiffness did not differ between groups. Not injured-patient healing.
- [12]Praet and colleagues: collagen with Achilles rehabilitation · Source date: January 2, 2019 · Reviewed
Small crossover pilot of a specific collagen preparation with a calf-exercise program; symptoms/function, not all-brand injury repair.
- [13]NIH ODS: dietary supplements, what you need to know · Source date: Source date is shown on the original page · Reviewed
Labels, quality, interactions, special situations and the limits of supplement oversight.
- [14]MedlinePlus: how wounds heal · Source date: Source date is shown on the original page · Reviewed
Wound healing, scars and reasons healing can be delayed; no fixed personal timeline.
- [15]FDA: regenerative-medicine consumer information · Source date: Source date is shown on the original page · Reviewed
Product/indication and clinical-evidence questions for regenerative offerings; no clinic recommendation.
- [16]NIAMS: sports injury diagnosis and care · Source date: Source date not stated · Reviewed
Injury assessment, severity, rehabilitation and return decisions; no personal protocol.
- [17]WADA: 2026 prohibited list · Source date: Effective January 1, 2026 · Reviewed
Sport-specific prohibited-substance framework. Check the list applicable on the competition date.
- [18]USADA: 2026 Clean Sport Handbook · Source date: 2026 · Reviewed
Sport rules, supplements, certification limitations and therapeutic-use exemption context.
Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.
See a problem or outdated information? Tell us.